Regulation of Epithelial-to-Mesenchymal Transition by Alternative Translation Initiation Mechanisms and Its Implications for Cancer Metastasis

被引:16
作者
Bera, Amit [1 ]
Lewis, Stephen M. [1 ,2 ,3 ]
机构
[1] Atlantic Canc Res Inst, Moncton, NB E1C 8X3, Canada
[2] Univ Moncton, Dept Chem & Biochem, Moncton, NB E1A 3E9, Canada
[3] Beatrice Hunter Canc Res Inst, Halifax, NS B3H 4R2, Canada
关键词
epithelial-to-mesenchymal transition (EMT); IRES; m(6)A-mediated translation; ITAF; cancer; metastasis; IRES-MEDIATED TRANSLATION; RIBOSOME ENTRY SITES; MESSENGER-RNA; BREAST-CANCER; LAMININ B1; INTERNAL INITIATION; PROTEIN-SYNTHESIS; MIR-200; FAMILY; ACTING FACTORS; EXPRESSION;
D O I
10.3390/ijms21114075
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Translation initiation plays a critical role in the regulation of gene expression for development and disease conditions. During the processes of development and disease, cells select specific mRNAs to be translated by controlling the use of diverse translation initiation mechanisms. Cells often switch translation initiation from a cap-dependent to a cap-independent mechanism during epithelial-to-mesenchymal transition (EMT), a process that plays an important role in both development and disease. EMT is involved in tumor metastasis because it leads to cancer cell migration and invasion, and is also associated with chemoresistance. In this review we will provide an overview of both the internal ribosome entry site (IRES)-dependent and N-6-methyladenosine (m(6)A)-mediated translation initiation mechanisms and discuss how cap-independent translation enables cells from primary epithelial tumors to achieve a motile mesenchymal-like phenotype, which in turn drives tumor metastasis.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 50 条
  • [31] SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis
    Simic, Petra
    Williams, Eric O.
    Bell, Eric L.
    Gong, Jing Jing
    Bonkowski, Michael
    Guarente, Leonard
    CELL REPORTS, 2013, 3 (04): : 1175 - 1186
  • [32] miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4
    Xue, Yubao
    Xu, Wenjing
    Zhao, Wei
    Wang, Wei
    Zhang, Dahong
    Wu, Ping
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 86 : 426 - 433
  • [33] The Epithelial-to-Mesenchymal Transition in Development and Cancer
    Francou, Alexandre
    Anderson, Kathryn V.
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 2020, 4 : 197 - 220
  • [34] Melatonin and Its Role in the Epithelial-to-Mesenchymal Transition (EMT) in Cancer
    Martinez-Campa, Carlos
    Alvarez-Garcia, Virginia
    Alonso-Gonzalez, Carolina
    Gonzalez, Alicia
    Cos, Samuel
    CANCERS, 2024, 16 (05)
  • [35] Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer
    Jacob, Sheeba
    Nayak, S.
    Fernandes, Gwendolyn
    Barai, R. S.
    Menon, S.
    Chaudhari, U. K.
    Kholkute, S. D.
    Sachdeva, Geetanjali
    ENDOCRINE-RELATED CANCER, 2014, 21 (03) : 473 - 486
  • [36] The role of exosomes in the promotion of epithelial-to-mesenchymal transition and metastasis
    Visan, Kekoolani S.
    Lobb, Richard J.
    Moller, Andreas
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2020, 25 : 1022 - 1057
  • [37] Epithelial-to-Mesenchymal Transition in Metastasis: Focus on Laryngeal Carcinoma
    Goulioumis, Anastasios
    Gyftopoulos, Kostis
    BIOMEDICINES, 2022, 10 (09)
  • [38] SPOCK1 Involvement in Epithelial-to-Mesenchymal Transition: A New Target in Cancer Therapy?
    Sun, Li-rui
    Li, Si-yu
    Guo, Qiu-shi
    Zhou, Wei
    Zhang, Hong-mei
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3561 - 3569
  • [39] Stem Cell State and the Epithelial-to-Mesenchymal Transition: Implications for Cancer Therapy
    Donnenberg, Vera S.
    Donnenberg, Albert D.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (06) : 603 - 619
  • [40] Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
    Zafari, Nima
    Velayati, Mahla
    Nassiri, Mohammadreza
    Khazaei, Majid
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Avan, Amir
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (28) : 2298 - 2311